Fetal Stem Cells Use in Complex Treatment of Patients with Acquired Aplastic Anemia and Therapy Effect on Recovery of Hematopoietic Functions
International Journal of Genetics and Genomics
Volume 4, Issue 6, December 2016, Pages: 55-60
Received: Jan. 25, 2017; Accepted: Feb. 20, 2017; Published: Mar. 21, 2017
Views 1926      Downloads 90
Authors
Mikhail M. Shulak, Cell Therapy Center EmCell, Kyiv, Ukraine
Mariya O. Klunnyk, Cell Therapy Center EmCell, Kyiv, Ukraine
Iryna G. Matiyashchuk, Cell Therapy Center EmCell, Kyiv, Ukraine
Olena V. Ivankova, Cell Therapy Center EmCell, Kyiv, Ukraine
Marina V. Skalozub, Laboratory Department, Cell Therapy Center EmCell, Kyiv, Ukraine
Nataliia S. Sych, Cell Therapy Center EmCell, Kyiv, Ukraine
Mariya P. Demchuk, Cell Therapy Center EmCell, Kyiv, Ukraine
Andriy A. Sinelnyk, Cell Therapy Center EmCell, Kyiv, Ukraine
Timur V. Karayev, Cell Therapy Center EmCell, Kyiv, Ukraine
Khrystyna I. Sorochynska, Stem Cell Bank, Cell Therapy Center EmCell, Kyiv, Ukraine
Article Tools
Follow on us
Abstract
The principal objective was studying effects of complex treatment using fetal stem cells (FSCs) on recovery of hematopoietic function. 50 patients suffering from aplastic anemia of different disease severity were under study and underwent complex treatment by use of cryopreserved suspensions containing fetal liver cells extracted from 7-12 week gestation fetuses. During the above study we proved effectiveness of FSCs use for the patients with acquired aplastic anemia (AAA). Positive effects on patient’s subjective assessment of his/her condition along with an objective increase of tolerance to physical exercises were reported as early as during the first week after FSCs transplantation. We also recorded a stabilization of erythrocytes count, hemoglobin levels, platelets and leukocytes values in all patients under study. Reverse of infectious, hemorrhagic and anemic syndromes was achieved after treatment by use of FSCs. Significantly high erythrocytes and leucocytes counts controlled by laboratory tests together with reverse of anemia, hemorrhagic signs and infectious syndromes in the patients were also remarkable over 14 days after treatment. Within 7 days the patients felt improvement of their general state and increased tolerance to physical exercises. It has been proved that complex treatment by use of FSCs along with conventional therapy leads to stabilization of laboratory blood parameters and improved life quality among the patients with aplastic anemia.
Keywords
Acquired Aplastic Anemia, Fetal Stem Cells, Recovery of Blood Hematopoietic Function, Myelodysplasia
To cite this article
Mikhail M. Shulak, Mariya O. Klunnyk, Iryna G. Matiyashchuk, Olena V. Ivankova, Marina V. Skalozub, Nataliia S. Sych, Mariya P. Demchuk, Andriy A. Sinelnyk, Timur V. Karayev, Khrystyna I. Sorochynska, Fetal Stem Cells Use in Complex Treatment of Patients with Acquired Aplastic Anemia and Therapy Effect on Recovery of Hematopoietic Functions, International Journal of Genetics and Genomics. Vol. 4, No. 6, 2016, pp. 55-60. doi: 10.11648/j.ijgg.20160406.13
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Guidelines for the Diagnosis and Management of Adult Aplastic Anaemia; British Committee for Standards in Haematology (2015).
[2]
Guo D, Liu Q, Li B, et al; Severe aplastic anemia preceding acute monocytic leukemia in an adult with acquired trisomy 21: A case report. Oncol Lett. 2014 Feb; 7 (2): 565-567. Epub 2013 Dec 3.
[3]
Biswajit H, Pratim PP, Kumar ST, et al; Aplastic anemia: a common hematological abnormality among peripheral pancytopenia. N Am J Med Sci. 2012 Sep; 4 (9): 384-8. doi: 10.4103/1947-2714.100980.
[4]
Dror Y, Freedman MH. Inherited forms of bone marrow failure. In: Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA: Elsevier; 2013.
[5]
Rovó A, Tichelli A, Dufour C, SAA-WP EBMT. Diagnosis of acquired aplastic anemia. Bone Marrow Transplant 2013; 48: 162.
[6]
Bagby GC. Aplastic anemia and related bone marrow failure states. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016.
[7]
Tichelli A, Marsh JC; Treatment of aplastic anaemia in elderly patients aged >60 years. Bone Marrow Transplant. 2013 Feb; 48 (2): 180-2. doi: 10.1038/bmt.2012.224. Epub 2012 Nov 26.
[8]
Peinemann F, Bartel C, Grouven U. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia. Cochrane Database Syst Rev 2013; CD006407.
[9]
Dasouki MJ, Rafi SK, Olm-Shipman AJ, et al. Exome sequencing reveals a thrombopoietin ligand mutation in a Micronesian family with autosomal recessive aplastic anemia. Blood 2013; 122: 3440.
[10]
Kordasti S, Marsh J, Al-Khan S, et al. Functional characterization of CD4+ T cells in aplastic anemia. Blood 2012; 119: 2033.
[11]
Li Y, Li X, Ge M, Shi J, Qian L, Zheng Y, et al. (2011) Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: a single-center experience. Ann Hematol 90: 529-537. pmid: 21207031.
[12]
Scheinberg P, Young NS (2012) How I treat acquired aplastic anemia. Blood 120: 1185-1196. doi: pmid: 22517900.
[13]
Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood. 2011.
[14]
Valdez JM, Scheinberg P, Nunez O, et al. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis 2011; 52: 726.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186